Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic devices manufacturer is preparing 510(k) submissions for two constrained hip products, the ZCA "All-Poly" acetabular cup and Trilogy acetabular system constrained liner, following the recent downclassification of constrained hip liners from Class III to Class II (1"The Gray Sheet" May 6, 2002, p. 19). Announced by FDA April 30 and effective May 30, the final rule reclassifying of hip joint metal/polymer constrained cemented or uncemented prostheses has the effect of "potentially shortening the product review and approval cycle from years to months," Zimmer notes...

You may also be interested in...



CDRH-Wide Preamendments Reclassifications Could Finish In 2-3 Years

CDRH's Division of Clinical Laboratory Devices anticipates wrapping up preamendments reclassifications in six to 12 months

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel